{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:05:55Z","timestamp":1773291955372,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1124\/jpet.103.062182","type":"journal-article","created":{"date-parts":[[2004,2,25]],"date-time":"2004-02-25T22:12:55Z","timestamp":1077747175000},"page":"935-940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Cardiac Ion Channel Effects of Tolterodine"],"prefix":"10.1016","volume":"308","author":[{"given":"Jiesheng","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongge","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junzhi","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sungtaek","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Rampe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.103.062182_bib1","doi-asserted-by":"crossref","unstructured":"Ben-David J and Zipes DP (1993) Torsades de pointes and proarrhythmia. Lancet 341: 1578\u20131582.","DOI":"10.1016\/0140-6736(93)90708-O"},{"key":"10.1124\/jpet.103.062182_bib2","doi-asserted-by":"crossref","unstructured":"Brynne N, Dalen P, Alvan G, Bertilsson L, and Gabrielsson J (1998) Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine. Clin Pharmacol Ther 63: 529\u2013539.","DOI":"10.1016\/S0009-9236(98)90104-7"},{"key":"10.1124\/jpet.103.062182_bib3","doi-asserted-by":"crossref","unstructured":"De Ponti F, Poluzzi E, and Montanaro N (2000) QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 56: 1\u201318.","DOI":"10.1007\/s002280050714"},{"key":"10.1124\/jpet.103.062182_bib4","doi-asserted-by":"crossref","unstructured":"Hamill OP, Marty A, Neher E, Sakmann B, and Sigworth FJ (1981) Improved patch clamp techniques for high resolution current recording from cells and cell free membrane patches. Pfluegers Arch 391: 85\u2013100.","DOI":"10.1007\/BF00656997"},{"key":"10.1124\/jpet.103.062182_bib5","doi-asserted-by":"crossref","unstructured":"Hills CJ, Winter SA, and Balfour JA (1998) Tolterodine. Drugs 55: 813\u2013820.","DOI":"10.2165\/00003495-199855060-00008"},{"key":"10.1124\/jpet.103.062182_bib6","doi-asserted-by":"crossref","unstructured":"Jones SE, Ogura T, Shuba LM, and McDonald TF (1998) Inhibition of the rapid component of the delayed-rectifier K+ current by therapeutic concentrations of the antispasmodic agent terodiline. Br J Pharmacol 125: 1138\u20131143.","DOI":"10.1038\/sj.bjp.0702173"},{"key":"10.1124\/jpet.103.062182_bib7","doi-asserted-by":"crossref","unstructured":"Kang J, Wang L, Cai F, and Rampe D (2000) High affinity blockade of the HERG cardiac K+ channel by the neuroleptic pimozide. Eur J Pharmacol 392: 137\u2013140.","DOI":"10.1016\/S0014-2999(00)00123-0"},{"key":"10.1124\/jpet.103.062182_bib8","doi-asserted-by":"crossref","unstructured":"Kuryshev YA, Brown AM, Wang L, Benedict CR, and Rampe D (2000) Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther 295: 614\u2013620.","DOI":"10.1016\/S0022-3565(24)38946-3"},{"key":"10.1124\/jpet.103.062182_bib9","doi-asserted-by":"crossref","unstructured":"Larsson G, Hallen B, and Nilvebrant L (1999) Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology 53: 990\u2013998.","DOI":"10.1016\/S0090-4295(98)00629-3"},{"key":"10.1124\/jpet.103.062182_bib10","doi-asserted-by":"crossref","unstructured":"Layton D, Pearce GL, and Shakir SAW (2001) Safety profile of tolterodine as used in general practice in England. Drug Safety 24: 703\u2013713.","DOI":"10.2165\/00002018-200124090-00005"},{"key":"10.1124\/jpet.103.062182_bib11","doi-asserted-by":"crossref","unstructured":"Millard R, Tuttle J, Moore K, Susset J, Clarke B, Dwyer P, and Davis BE (1999) Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 161: 1551\u20131555.","DOI":"10.1016\/S0022-5347(05)68951-3"},{"key":"10.1124\/jpet.103.062182_bib12","doi-asserted-by":"crossref","unstructured":"Mohammad S, Zhou Z, Gong Q, and January CT (1997) Blockage of the HERG human cardiac K+ channel by the gastric prokinetic agent cisapride. Am J Physiol 273: H2534\u2013H2538.","DOI":"10.1152\/ajpheart.1997.273.5.H2534"},{"key":"10.1124\/jpet.103.062182_bib13","doi-asserted-by":"crossref","unstructured":"Nilvebrant L (2001) Clinical experiences with tolterodine. Life Sci 68: 2549\u20132556.","DOI":"10.1016\/S0024-3205(01)01051-7"},{"key":"10.1124\/jpet.103.062182_bib14","doi-asserted-by":"crossref","unstructured":"Olsson B and Szamosi J (2001) Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet 40: 227\u2013235.","DOI":"10.2165\/00003088-200140030-00006"},{"key":"10.1124\/jpet.103.062182_bib15","doi-asserted-by":"crossref","unstructured":"Paul AA, Leishman DJ, Witchel HJ, and Hancox JC (2001) Effects of the class III antiarrhythmic agent dofetilide (UK-68, 798) on L-type calcium current from rabbit ventricular myocytes. J Pharm Pharmacol 53: 1671\u20131678.","DOI":"10.1211\/0022357011778061"},{"key":"10.1124\/jpet.103.062182_bib16","doi-asserted-by":"crossref","unstructured":"Pearlstein R, Vaz R, and Rampe D (2003) Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. J Med Chem 46: 2017\u20132022.","DOI":"10.1021\/jm0205651"},{"key":"10.1124\/jpet.103.062182_bib17","doi-asserted-by":"crossref","unstructured":"Rampe D, Roy M-L, Dennis A, and Brown AM (1997) A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 417: 28\u201332.","DOI":"10.1016\/S0014-5793(97)01249-0"},{"key":"10.1124\/jpet.103.062182_bib18","doi-asserted-by":"crossref","unstructured":"Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PKS, Strang I, Sullivan AT, Wallis R, et al. (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsades de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58: 32\u201345.","DOI":"10.1016\/S0008-6363(02)00846-5"},{"key":"10.1124\/jpet.103.062182_bib19","doi-asserted-by":"crossref","unstructured":"Roy M-L, Dumaine R, and Brown AM (1996) HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 94: 817\u2013823.","DOI":"10.1161\/01.CIR.94.4.817"},{"key":"10.1124\/jpet.103.062182_bib20","doi-asserted-by":"crossref","unstructured":"Salata JJ, Jurkiewicz NK, Wallace AA, Stupienski RF, Guinosso PJ, and Lynch JJ (1995) Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res 76: 110\u2013119.","DOI":"10.1161\/01.RES.76.1.110"},{"key":"10.1124\/jpet.103.062182_bib21","doi-asserted-by":"crossref","unstructured":"Sanguinetti MC, Jiang C, Curran ME, and Keating MT (1995) A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81: 299\u2013307.","DOI":"10.1016\/0092-8674(95)90340-2"},{"key":"10.1124\/jpet.103.062182_bib22","doi-asserted-by":"crossref","unstructured":"Thomas SH, Higham PD, Hartigan GK, Kamali F, Wood P, Campbell RW, and Ford GA (1995) Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence. Br Heart J 74: 53\u201356.","DOI":"10.1136\/hrt.74.1.53"},{"key":"10.1124\/jpet.103.062182_bib23","doi-asserted-by":"crossref","unstructured":"Wang J, Della-Penna K, Wang H, Karczewski J, Connolly TM, Koblan KS, Bennett PB, and Salata JJ (2003) Functional and pharmacological properties of canine ERG potassium channels. Am J Physiol 284: H256\u2013H267.","DOI":"10.1152\/ajpheart.00220.2002"},{"key":"10.1124\/jpet.103.062182_bib24","doi-asserted-by":"crossref","unstructured":"Zhang S, Zhou Z, Gong Q, Makielski JC, and January CT (1999) Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 84: 989\u2013998.","DOI":"10.1161\/01.RES.84.9.989"},{"key":"10.1124\/jpet.103.062182_bib25","doi-asserted-by":"crossref","unstructured":"Zhou Z, Vorperian VR, Gong Q, Zhang S, and January CT (1999) Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol 10: 836\u2013843.","DOI":"10.1111\/j.1540-8167.1999.tb00264.x"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524312066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524312066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.103.062182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:47:47Z","timestamp":1739998067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524312066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["S0022356524312066"],"URL":"https:\/\/doi.org\/10.1124\/jpet.103.062182","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2004,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac Ion Channel Effects of Tolterodine","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.103.062182","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2004 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}